An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms

To answer these questions, further understanding of the burden kinetics of COVID-19 and its correlation with neurological clinical outcomes, endogenous antibody responses to vaccines, pharmacokinetics of neutralizing mAbs, and action against emerging viral mutant variants is needed.

📌 3 Maddede Bu Makale

🎯

Amaç & Hipotez:Various recently reported mutant variants, candidate and urgently approved current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many current situations with severe neurological damage and symptoms as well as respiratory tract disorders have begun to be reported.

📊

Temel Bulgular & Veri:Here, we review lessons learned from the use of novel mutant variants of the COVID-19 virus, immunization, new drug solutions, and antibody therapies for infections.

💡

Sonuç & Katkı:To answer these questions, further understanding of the burden kinetics of COVID-19 and its correlation with neurological clinical outcomes, endogenous antibody responses to vaccines, pharmacokinetics of neutralizing mAbs, and action against emerging viral mutant variants is needed.

🔬Tür:Literatür & Derleme Çalışması

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Alan Parametreleri

Özet

Various recently reported mutant variants, candidate and urgently approved current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many current situations with severe neurological damage and symptoms as well as respiratory tract disorders have begun to be reported. In particular, drug, vaccine, and neutralizing monoclonal antibodies (mAbs) have been developed and are currently being evaluated in clinical trials. Here, we review lessons learned from the use of novel mutant variants of the COVID-19 virus, immunization, new drug solutions, and antibody therapies for infections. Next, we focus on the B 1.1.7, B 1.351, P.1, and B.1.617 lineages or variants of concern that have been reported worldwide, the new manifestations of neurological manifestations, the current therapeutic drug targets for its treatment, vaccine candidates and their efficacy, implantation of convalescent plasma, and neutralization of mAbs. We review specific clinical questions, including many emerging neurological effects and respiratory tract injuries, as well as new potential biomarkers, new studies in addition to known therapeutics, and chronic diseases of vaccines that have received immediate approval. To answer these questions, further understanding of the burden kinetics of COVID-19 and its correlation with neurological clinical outcomes, endogenous antibody responses to vaccines, pharmacokinetics of neutralizing mAbs, and action against emerging viral mutant variants is needed.

🔖

Bu Makaleye Atıf Yap

KONUK, M., OKTAY, E. Ö., KAMAN, T., KARASAKAL, Ö. F., TUNCAY, S., ÖZCAN, Ö. Ö., SOYLAMIŞ, T., KARAHAN, M. (2022). An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms. Turkish Journal of Biology, Cilt: 45 - Sayı: 4, 342–357. https://ajindex.com/articles/600144

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

Almubaid Z, Al-Mubaid H. (2021). Analysis and comparison of genetic variants and mutations of the novel coronavirus SARS-CoV-2. Gene Reports 23: 101064. doi: 10.1016/j. genrep.2021.101064 Antony AR, Haneef Z (2020). Systematic review of EEG findings in 617 patients diagnosed with COVID-19. Seizure. 83: 234-241. doi: 10.1016/j.seizure.2020.10.014 Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S et al. (2021). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine 384 (5): 403-416. doi: 10.1056/nejmoa2035389 Baig AM, Khaleeq A, Ali U, Syeda H (2020). Evidence of the COVID-19 virus targeting the CNS: tissue distribution, hostvirus interaction, and proposed neurotropic mechanisms. ACS Chemical Neuroscience 11 (7): 995-998. doi: 10.1021/ acschemneuro.0c00122 Beigel JH (2018). Polyclonal and monoclonal antibodies for the treatment of influenza. Current Opinion in Infectious Diseases, 31 (6): 527-534. doi: 10.1097/QCO.0000000000000499 Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P et al. (2021). Novel SARS-CoV-2 variants: the pandemics within the pandemic. Clinical Microbiology and Infection. doi: 10.1016/j. cmi.2021.05.022 Cai Q, Yang M, Liu D, Chen J, Shu D et al. (2020). Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering. doi: 10.1016/j.eng.2020.03.007 Callejon-Leblic MA, Moreno-Luna R, Del Cuvillo A, Reyes-Tejero IM, Garcia-Villaran MA et al. (2021). Loss of smell and taste can accurately predict COVID-19 infection: a machinelearning approach. Journal of Clinical Medicine 10 (4): 570. doi: 10.3390/jcm10040570 Charkiewicz R, Nikliński J, Biecek P, Kiśluk J, Pancewicz S et al. (2021). The first SARS-CoV-2 genetic variants of concern (VOC) in Poland: The concept of a comprehensive approach to monitoring and surveillance of emerging variants. Advances in Medical Sciences 66 (2): 237-245. doi: 10.1016/j. advms.2021.03.005 Chen X, Laurent S, Onur OA, Kleineberg NN, Fink GR et al. (2021). A systematic review of neurological symptoms and complications of COVID-19. Journal of Neurology 268 (2): 392-402. doi: 10.1007/s00415-020-10067-3
Cheng MH, Krieger JM, Kaynak B, Arditi M, Bahar I (2021). Impact of South African 501.V2 variant on SARS-CoV-2 spike infectivity and neutralization: A structure-based computational assessment. BioRxiv. doi: 10.1101/2021.01.10.426143 Collier DA, De Marco A, Ferreira IATM, Meng B, Datir RP et al. (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccineelicit